Cholera toxin (CT) is the most potent known mucosal adjuvant, but its toxicity precludes its use in humans. Here, in an attempt to develop safe and effective mucosal adjuvants, we compared immune responses to simian immunodeficiency virus (SIV) virus-like particles (VLPs) after intranasal coimmunization with RANTES, CpG oligodeoxynucleotides (ODN), or CT. Antibody analysis demonstrated that RANTES and CpG ODN had capacities for mucosal adjuvanticity, i.e., for enhancing serum and vaginal antibodies specific to SIV Env, similar to those for CT. RANTES and CpG ODN skewed serum antibodies predominantly to the immunoglobulin G2a isotype. Most importantly, RANTES and CpG ODN were more effective than CT in increasing neutralizing titers of both serum and vaginal antibodies. After intranasal coadministration with VLPs, RANTES or CpG ODN also induced increased levels of gamma interferon (IFN-␥)-producing lymphocyte and cytotoxic T-lymphocyte activities in both spleen and lymph nodes but did not increase the levels of interleukin-4-producing lymphocytes. The results suggest that RANTES and CpG ODN enhance immune responses in a T-helper-cell-type-1 (Th1)-oriented manner and that they can be used as effective mucosal adjuvants for enhancing both humoral and cellular immune responses in the context of VLPs, which are particulate antigens.
The mucosal surface is the primary site where the majority of infectious agents are first encountered. Until now, most vaccines have been given parenterally by intramuscular, subcutaneous, or intradermal injection. Parenteral delivery of a nonreplicating antigen induces mostly systemic immunity and very rarely induces mucosal immune responses. In contrast, mucosal antigen delivery can trigger mucosal immunity at local and distant sites as well as systemic immune responses and is thus an advantageous immunization protocol. However, mucosal immunization generally requires the use of adjuvants for induction of immune responses. Bacterial toxins, such as cholera toxin (CT) and heat-labile enterotoxin, are commonly used as potent mucosal adjuvants in animal models. However, these bacterial toxins may not be acceptable for use in humans because of their toxicity. It is therefore essential to develop an alternative mucosal adjuvant for use in humans.
It has been found that bacterial DNA, but not vertebrate DNA, can also be a potent activator of lymphocytes. Bacterial DNA contains unmethylated CpG dinucleotide motifs at much higher frequencies than vertebrate DNA (27, 30, 55) . The CpG motif DNA, most often given in the form of synthetic oligodeoxynucleotides (CpG ODN), provides broad adjuvant effects. Much work on using CpG ODN as an adjuvant has been done by parenteral immunization of mice and nonhuman primates (7, 9, 24, 37, 55) . In addition, recent studies have shown that mucosal delivery of protein antigens using CpG ODN as an adjuvant results in enhancement of systemic and mucosal immune responses to coadministered antigens including hepatitis B virus surface antigen (39, 40) , ␤-galactosidase (19) , tetanus toxoid (41) , human immunodeficiency virus (HIV) gp120 (18) , herpes simplex virus type 1 glycoprotein B (13) , and inactivated influenza virus (43) . However, its adjuvanticity has not been tested in the context of virus-like particle (VLP) antigens.
Chemokines are small chemoattractant cytokines and function as early-acting innate effector molecules to attract immune cells during foreign invasion. RANTES (regulated upon activation, normal T-cell expressed and secreted), a chemokine, is mainly secreted by epithelial cells, natural killer cells, and lymphocytes (38, 51, 58, 74) . RANTES expression is induced in epithelial cells by viral or bacterial infection or cytokine stimulation (38, 74) . Also, human nasal-derived epithelial cells secrete chemokines such as RANTES and interleukin-8 (IL-8) in response to virus infection (52, 57) . However, it is largely unknown whether RANTES can influence mucosal immune responses. A recent study has shown that RANTES is able to enhance antigen-specific serum and mucosal antibody responses when mucosally coadministered with ovalbumin as a model antigen (35) .
Both humoral and cellular immune responses seem to be important components in the development of HIV vaccines. It has been shown that VLPs can be produced from cells infected with recombinant vaccinia viruses (rVV) or baculoviruses expressing HIV or simian immunodeficiency virus (SIV) gag and env genes (11, 15, 68, 73, 75) or from cell lines expressing both genes (29) . Parenteral immunization studies demonstrated that HIV VLPs could induce humoral as well as cellular immune responses (45, 50, 53, 69) . Moldoveanu et al. reported the induction of antibody responses to SIV VLPs by mucosal routes after priming with a recombinant vaccinia virus expressing the SIV Env protein (44) . However, the mucosal immune responses to HIV and SIV VLPs have not been completely characterized. In an attempt to find a safe and effective mucosal adjuvant for VLPs, we compared the adjuvant effects of CT with those of CpG DNA and RANTES by intranasal coimmunization with SIV VLPs.
MATERIALS AND METHODS
Adjuvants. CT and RANTES were purchased from Sigma (St. Louis, Mo.) and Peprotech (Rocky Hill, N.J.), respectively. Phosphorothioate CpG ODN were synthesized and purified by high-pressure liquid chromatography by SigmaGenosys (The Woodlands, Tex.). Two different CpG ODN were suspended in phosphate-buffered saline (PBS) buffer, equally mixed, and used to immunize mice; one is 5Ј-TCCATGACGTTCCTGACGTT-3Ј, and the other is 5Ј-TGAC TGTGAACGTTCGAGATGA-3Ј. Both of the ODN sequences were used as adjuvants by other investigators (13, 19, 39, 44) .
Production of SIV VLPs. Spodoptera frugiperda insect (Sf9) cells (Invitrogen) were maintained in serum-free SF900 II medium (GIBCO-BRL) at 28°C. The production of SIVmac239 VLPs using a recombinant baculovirus (rBV) expression system was previously described (73) . Briefly, Sf9 cells were coinfected with two independent rBVs expressing SIV Gag and SIV Env at multiplicities of infection of 2 and 5, respectively. At day 3 postinfection, the culture medium was collected and centrifuged at 1,500 ϫ g for 20 min. The supernatant was filtered through a 0.45-m-pore-size filter, and VLPs were pelleted at 120,000 ϫ g for 2 h at 4°C. After VLPs were washed by suspension in PBS buffer and ultracentrifugation, pelleted VLPs were finally resuspended in PBS buffer and used for immunization. The total protein concentration of VLPs was determined by a Bio-Rad (Hercules, Calif.) protein assay. The incorporation of the SIV Env protein into VLPs was determined by Western blot analysis using monkey anti-SIV sera (73) .
Immunization protocol. Female BALB/c mice 6 to 8 weeks of age were purchased from Charles River and used in all experiments. Intranasal immunizations were performed with SIV VLPs (40 g), either alone or mixed with 10 g of CpG ODN or 1.5 g of RANTES or 10 g of CT. All immunizing reagents were suspended in 45 l of PBS buffer, and individual mice received 15 l three times with a 3-h resting interval between injections (total volume, 45 l). Mice were anesthetized slightly with isoflurane and held inverted with nose down until droplets of vaccine that were applied to both external nares were completely inhaled. Each group consisted of six mice, and mice were immunized at weeks 0, 2, 4, and 6.
Sample collections. Blood samples were collected by retro-orbital plexus puncture after anesthesia with isoflurane. Saliva was collected after intraperitoneal injection of 2 g of carbamylcholine chloride to stimulate flow, and vaginal lavage fluids were collected by washing the vagina with 200 l of PBS. Lungs and large intestines with feces were collected at 8 weeks (2 weeks after final immunization), and a perfusion-extraction method was employed for immunoglobulin A (IgA) determination (21) . Lung tissue was washed three times in a large volume of PBS to wash out any contaminating blood. Due to the possible difficulties in collecting fecal samples from individual mice, we measured the IgA antibodies in extracts of intestinal tissues containing feces. Lung and intestine tissues were weighed, cut into small pieces (2 to 3 mm long), suspended in extraction buffer (2% saponin-0.1% NaN 3 in PBS), and rocked overnight (100 mg of lung in 400 l of extraction buffer and 100 mg of intestine in 200 l of extraction buffer). All samples were stored at Ϫ20°C prior to antibody titration.
ELISA. For determination of antibodies specific for the SIVmac239 Env protein, enzyme-linked immunosorbent assay (ELISA) plates were coated with purified SIV Env in PBS (3 g/ml) and blocked with 2% bovine serum albumin. The SIVmac239 Env protein was purified from HEp-2 cells infected with rVV-SIVmac239 Env by using a lectin affinity column as described previously (12, 22, 23 ). An rVV expressing the SIV Env protein (rVV-SIV Env) was previously described (68) . For determination of total IgA antibodies, ELISA plates were coated with goat anti-mouse Ig antibodies (Southern Biotechnology, Birmingham, Ala.). Diluted samples were added to SIV Env-coated ELISA plates and incubated overnight at 4°C or for 4 h at room temperature. After a washing, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG, IgG1, and IgG2a (Southern Biotechnology) were used for serum samples and HRPconjugated goat anti-mouse IgA was used for mucosal samples (vaginal wash, saliva, lung, and intestine). HRP substrate ABTS (2, 2Ј-azinobis[3-ethylbenzthiazolinesulfonic acid]) containing H 2 O 2 (Sigma) was used to develop color, and optical density at 405 nm (OD 405 ) was read by an ELISA reader (MTX Lab Systems). Antibody concentrations were determined by comparing the readings for experimental samples with the standard curves for purified mouse IgG, IgG1, IgG2a, and IgA and are represented as arithmetic means Ϯ 1 standard error (SE). The statistical significance of the difference between any two groups was calculated by Student's t test, represented as a P value, and applied to all analyses.
Cell preparations. Spleen, cervical and mesenteric lymph nodes (LN), and Peyer's patches (PP) were obtained from individual mice, and minced between the frosted ends of glass slides. Both cervical and mesenteric LN were combined and used as a source of LN cells. To remove erythrocytes, spleen cells were treated with 0.1 M ammonium chloride buffer at pH 7.4 for 2 min at room temperature and the remaining cells were then washed in RPMI medium with 10% fetal bovine serum (FBS). Cells suspended in medium were filtered through fine metal screens or nylon membranes (Fisher) to remove cellular debris. After being stained with trypan blue, live cells were counted by light microscopy and used for enzyme-linked immunospot (ELISPOT), cell proliferation, and cytotoxic T-lymphocyte (CTL) analyses.
ELISPOT and proliferation assays. All antibodies against mouse cytokines used in ELISPOT assays were purchased from PharMingen (San Diego, Calif.). Anti-mouse gamma interferon (IFN-␥; R4-6A2) and IL-4 (BVD4-1D11) antibodies (4 g/ml in PBS) were used to coat Multiscreen 96-well filtration plates (Millipore) at 4°C overnight. After cytokine-coated plates were blocked with 10% FBS in RPMI 1640, freshly isolated splenocytes and LN cells (2 ϫ 10 6 cells for IFN-␥ and 1 ϫ 10 6 cells for IL-4) were added to each well. A mixture of SIV Env peptides (amino acids 211 to 230, CNTSVIQESCDKHYWDAIRF, and 231 to 250, RYCAPPGYALLRCNDTNYSG) (33, 36, 76) was added at a concentration of 5 g/ml, and plates were incubated for 36 h at 37°C. After plates were washed with PBS (containing 0.1% Tween 20) six times, biotinylated anti-mouse IFN-␥ (XMG1.2) and IL-4 (BVD6-24G2) antibodies (1 g/ml) were added to the plates. After a washing, spots in the plates were developed with stable diaminobenzidine (Research Genetics) for 3 to 5 min and counted in an ImmunoSpot ELISPOT reader (Cellular Technology, Ltd.). For proliferation assays, 50 l containing 5 ϫ 10 5 cells was mixed with 50 l of a CD4 T-cell epitope peptide (RQIINTWHKVGKNVYL; 20 g/ml) (77) and incubated for 3 days and live cells were determined by using a CellTiter96 nonradioactive cell proliferation assay (Promega, Madison, Wis.). Splenocytes and LN cells from nonimmunized mice were used as a negative control. This method, which measures the activity of mitochondrial dehydrogenases of viable cells, has been widely used to measure proliferation of various cell types including lymphocytes (14, 49, 59) . The degree of cell proliferation is presented as the ratio of OD 570 for cells from immunized mice to that for control cells from nonimmunized mice.
CTL analysis. P815 target cells (major histocompatibility complex [MHC] class I, H-2d) were prepared by infection with rVV expressing the SIVmac239
Env protein at a multiplicity of infection of 1. Infected P815 cells (10 4 cells) were harvested at 5 to 7 h postinfection and incubated with freshly isolated lymphocytes (spleen, LN, and PP) from immunized or naive mice at different effectorto-target cell (E:T) ratios. P815 cells infected with wild-type vaccinia virus were used as negative control target cells. The amount of cell lysis was measured with the CytoTox96 nonradioactive cytotoxicity assay (Promega). This assay measures lactate dehydrogenase, a stable cytosolic enzyme that is released upon cell lysis in the same way as 51 Cr is released in the radioactive assay. The results from these two assays were shown to be almost identical (10, 28) , and several studies used this nonradioactive cytotoxic assay for CTL analysis (2, 5, 42) . The percentage of specific target cell lysis was represented based on total cell lysis with 0.1% Triton X-100.
Neutralization assay. For neutralization assays, sMAGI cells (6) and SIVmac1A11 grown in HUT78 cells (American Type Culture Collection) were used as described previously (44) . SIVmac1A11, which is sensitive to neutralization, is a strain closely related to SIVmac239. In brief, sMAGI cells (3.5 ϫ 10 3 cells per well) were added to a 96-well plate 1 day before infection. Serum samples were heat inactivated (56°C, 30 min) and serially twofold diluted in Dulbecco's modified Eagle medium (DMEM) containing 10% FBS, and a final volume of 25 l was mixed with 25 l of diluted virus stock containing 100 infectious particles. The virus-serum mixtures were incubated at 37°C for 1 h and then added to sMAGI cells with DEAE-dextran at a final concentration of 15 g/ml. After 2 h of incubation, 150 l of DMEM was added. Medium was replaced after 1 day of incubation with DMEM-10% FBS containing 10 M zidovudine (Sigma). At day 3 postinfection, medium was removed and cells were fixed and stained as described previously (6) . The blue cells in the wells without antisera indicate the total number of infectious virus particles. Neutralization titers are presented as dilutions giving 50% reduction in the number of blue cells. For the neutralization assay using mucosal secretions, vaginal wash samples from three mice were pooled and the resulting two pools from each group (six mice per group) were analyzed for neutralization activities.
RESULTS
Adjuvant effect of RANTES and CpG DNA on inducing serum antibody responses to VLPs. CT is the most potent known mucosal adjuvant. Therefore, experiments were designed to compare the adjuvant efficacies of RANTES and CpG for enhancing the immune response to SIV VLPs with those of CT. The levels of anti-SIV Env antibodies in serum were greatly enhanced in all groups of mice after the second intranasal boost immunization as shown in Fig. 1A . Intranasal immunization with SIV VLPs in the absence of any adjuvant also induced SIV Env-specific serum antibody responses (Fig.  1A) . The increase in specific serum antibody levels was significantly higher in both groups of mice coimmunized with RANTES or CpG as the adjuvant than in the group of mice which received VLPs only (P ϭ 0.014 and 0.010, respectively). The adjuvant effect of RANTES was similar to that of CpG. The specific antibody level was highest in mice immunized with VLPs plus CT (P ϭ 0.001). However, the difference between the groups of mice which received RANTES or CpG as the adjuvant and the group of mice which received CT was not significant (P ϭ 0.18 for RANTES and P ϭ 0.49 for CpG). The results in Fig. 1A therefore indicate that RANTES and CpG have adjuvant capacities for inducing serum antibodies in the context of VLP intranasal immunization similar to those of CT.
The serum Ig isotypes of SIV Env-specific antibodies induced by VLPs in combination with RANTES or CpG or CT are shown in Fig. 1B . The SIV Env protein in the form of VLPs induced more IgG2a than IgG1 (ratio of IgG2a to IgG1, 1.56), in contrast to soluble protein antigens, which induce mostly antigen-specific IgG1 rather than IgG2a (20, 34, 35, 66) . Inclusion of RANTES and CpG in VLP intranasal immunization further increased the levels of IgG2a, resulting in IgG2a-toIgG1 ratios of 5.7 and 5.4, respectively. Both IgG1 and IgG2a specific to SIV Env were increased in mice intranasally immunized with VLPs plus CT, and the ratio of IgG2a to IgG1 was 3.0. The results of serum isotype analysis suggest that RANTES and CpG induced more-T-helper-cell-type-1 (Th1)-like immune responses.
Adjuvant effect of RANTES and CpG in inducing mucosal IgA responses. Induction of immune responses at mucosal sites is one of the main objectives for mucosal immunization. Overall, the levels of SIV Env-specific IgA antibodies were found to be higher in vaginal wash than in saliva (data not shown). Because total secreted IgA antibody levels show variations in individual samples, ratios of mucosal IgA antibodies specific to SIV Env to total IgA (specific IgA/total IgA ratios) for saliva, vaginal wash, lung, and large intestine were determined as shown in Fig. 2 . The ability of RANTES and CpG to enhance salivary IgA specific to SIV Env delivered in the form of VLPs was moderate, but the rise was statistically significant (P ϭ 0.012 and 0.013, respectively). The group immunized with VLPs plus CT induced ratios of salivary specific IgA/total IgA similar to those induced by RANTES-and CpG-coimmunized groups (Fig. 2B) . Surprisingly, the mice immunized with VLPs plus RANTES induced the highest ratio of vaginal specific IgA/total IgA antibodies ( Fig. 2A ; P ϭ 0.014). Groups of mice immunized with CpG or CT as the adjuvant showed moderately increased levels of vaginal IgA antibodies. The SIV Envspecific IgA/total IgA ratios after the fourth immunization (at week 8) in vaginal wash and saliva were similar to those after the third immunization (data not shown)
To determine the SIV Env-specific IgA antibodies in the large intestine and lung, tissues were excised, cut into small pieces, and extracted in saponin buffer. As shown in Fig. 2C for intestinal samples, a moderate increase of antigen-specific IgA antibodies was observed in groups coimmunized with RANTES or CT as the adjuvant (P ϭ 0.042 for RANTES and 0.028 for CT). For enhancing antigen-specific lung IgA antibodies, the adjuvant effect of both RANTES and CpG was significant (P ϭ 0.002 and 0.001, respectively) (Fig. 2D) . Overall, groups coimmunized with CT showed higher levels of total IgA antibodies, particularly in lung extracts and saliva, resulting in lower ratios of specific IgA/total IgA antibodies. The results of mucosal IgA antibody analysis indicate that both RANTES and CpG ODN have a capacity to enhance IgA immune responses after coadministration intranasally with the SIV VLP antigen. For enhancing vaginal IgA antibodies, RANTES was the most effective adjuvant tested. Effect of RANTES and CpG ODN on inducing neutralizing antibodies. In evaluating vaccines, one important criterion is the capacity to induce neutralizing antibodies which would be effective for preventing infection. As presented in Fig. 3 , we observed relatively high titers of neutralizing antibodies in serum induced by intranasal immunization with VLPs alone, which is similar to the results reported by Moldoveanu et al.
using SIV VLPs produced from rVV (44) . It is noteworthy that mice intranasally immunized with VLPs in combinations with RANTES or CpG showed fourfold-higher titers of neutralizing antibodies than the group of mice immunized with VLPs only (P ϭ 0.008 for RANTES and P ϭ 0.0002 for CpG ODN). Thus, there was a significant enhancement of neutralizing titers induced by addition of RANTES or CpG as the adjuvant. This is in contrast with results for CT, which did not significantly increase the neutralizing antibody titers in serum.
Although many studies have investigated mucosal immune responses, most of them focused on evaluating responses of antibodies that bind to specific antigens. The evaluation of neutralizing activities in mucosal secretions should be of prime importance in mucosal immunization. To determine the neutralizing activities in secretions, vaginal wash (Fig. 3B ) and lung extract (data not shown) samples were pooled together and analyzed for the neutralizing activities. Low neutralizing activities were detected in vaginal secretions and lung extract from mice immunized with VLPs alone. The mice immunized intranasally with VLPs plus RANTES showed the highest level of neutralizing activities in vaginal secretions, a sixfold increase compared to that in control mice immunized with VLPs in the absence of an adjuvant (P ϭ 0.01). The group of mice immunized with VLPs plus CpG showed a fourfold increase of neutralizing activity (P ϭ 0.02). The CT-coadministered group also showed a significant increase in the level of neutralizing activity in vaginal secretions (P ϭ 0.012), but the level was similar to or lower than those for the RANTES-or CpGcoadministered groups. Also, RANTES induced an increase in neutralizing activity of lung extracts similar to that induced by CT (data not shown). The results indicate that both RANTES and CpG can enhance the induction of neutralizing antibodies in both mucosal secretions and serum.
Effect of RANTES and CpG ODN on the induction of cytokine-producing lymphocytes. Another integral component of a successful AIDS vaccine is the induction of cellular immune responses, and particularly CTL activities important for killing infected cells and controlling disease progression. Cellular immune responses induced after mucosal immunization with VLPs are not well understood. Determining the pattern of cytokine production is one of the approaches for assessing cellular immune responses. Cells from spleens and LN of immunized mice were isolated at 2 weeks after the last immunization, and IFN-␥-producing lymphocytes were analyzed by ELISPOT as shown in Fig. 4 . In all groups immunized with VLPs, the number of cells producing IFN-␥ was higher in LN than in spleen (Fig. 4A) . Addition of RANTES to VLP immunization resulted in a moderate increase in IFN-␥-producing splenocytes but, surprisingly, induced the highest number of LN cells producing IFN-␥ (P ϭ 0.043). Spleen cells from the groups of mice immunized with VLPs plus CpG ODN or CT produced highly increased numbers of IFN-␥ spots compared to those from mice immunized with VLPs alone (P ϭ 0.042 for CpG ODN and P ϭ 0.03 for CT).
In contrast to the results with IFN-␥, splenocytes produced more IL-4-producing spots than LN cells (Fig. 4B) . Addition of RANTES or CpG ODN to VLP intranasal immunization resulted in a decrease in the number of IL-4-producing LN cells relative to total cell numbers. Only the group of mice immunized with VLPs plus CT showed a significant increase in IL-4-producing cells in both spleen (P ϭ 0.026) and LN (P ϭ 0.046) compared to the mice immunized with VLPs alone.
Overall, the ELISPOT results indicate that intranasal immunization with VLPs induced higher numbers of IFN-␥-producing cells in LN than in spleen and higher numbers of IL-4-producing cells in spleen than in LN. For inducing LN cells producing IFN-␥, RANTES is more effective than CpG ODN or CT. In the context of the VLP antigen, CpG ODN showed an adjuvant capacity for increasing the numbers of cells producing IFN-␥ in both spleen and LN similar to that of CT. In particular, CT induced greatly enhanced levels of IL-4-producing cells in both spleen and LN.
Effect of RANTES and CpG ODN on inducing cellular immune responses. To determine the CTL activity (Fig. 5) , P815 cells infected with rVV expressing SIV Env were used as target cells. Lymphocytes were isolated from spleen, LN, and PP 2 weeks after the last immunization. Naive controls showed about 5 to 10% CTL lysis of target cells nonspecifically, which did not change very much even at a high E:T cell ratio. Intranasal immunization with VLPs in the absence of an adjuvant induced CTL activities in spleen and LN at low levels (20 to 25% CTL lysis of target cells), but at higher levels than those in naive controls. Addition of CT or RANTES or CpG ODN to VLP intranasal immunization increased CTL activities of lymphocytes to 40 to 50% lysis of target cells at an E:T ratio of 50 (P Ͻ 0.05 for all). Similar increases in PP CTL activities were observed in the group of mice immunized with VLPs plus CT or CpG ODN (data not shown).
Finally, we determined the proliferation of lymphocytes from nonimmunized and immunized mice after CD4 T-helpercell peptide stimulation in vitro (Fig. 6) . Intranasal immunization with VLPs alone increased proliferation by twofold in LN and produced only slight increases of proliferation in spleen and PP. Lymphocytes from spleen, LN, and PP of mice intranasally immunized with VLPs plus CT showed the highest increases, with proliferation enhanced fourfold (P Ͻ 0.02). Inclusion of RANTES in VLP immunization enhanced LN lymphocyte proliferation (P Ͻ 0.04) to a level similar to that seen with CT (Fig. 6B) , and the effect of RANTES on splenocyte proliferation was slight but statistically significant (P Ͻ 0.04). Addition of CpG ODN to VLP immunization induced moderate proliferation in spleen (P Ͻ 0.02) and PP (P Ͻ 0.05) lymphocytes.
These results indicate that VLP intranasal administration induced low levels of CTL activities and proliferation in systemic and mucosal tissues. Addition of CpG ODN or RANTES to VLP intranasal immunization induced higher levels of CTL activities in spleen and LN, which were similar to the level seen by the addition of CT. Inclusion of CT as an adjuvant induced very strong proliferation responses in combination with VLP intranasal immunization. 
DISCUSSION
Mucosal vaccines are important to protect against the large number of infectious diseases that are transmitted via mucosal surfaces. Use of a safe and effective adjuvant would be of great value in the development of such mucosal vaccines. This study showed that coadministration of mice with RANTES and SIV VLPs increased the SIV Env-specific serum antibodies to levels similar to those achieved with CT coadministration and that the SIV Env-specific isotype was predominantly IgG2a. Also, intranasal coadministration of SIV VLPs plus RANTES highly induced the activation of LN cells as determined by IFN-␥ production, CTL activities, and proliferation. It was found that RANTES induced higher activation of cervical and mesenteric LN cells than of cells in other lymphoid tissues such as the spleen when intranasally coadministered with ovalbumin (35) . The level of IgG2a antibody is often associated with IFN-␥ production (8) and may account for the RANTES-mediated anti-SIV Env IgG2a antibody responses. The receptor for RANTES, CCR5 is preferentially expressed in Th1 type T cells (3) , which may explain the result that RANTES enhances mucosal responses in a Th1-oriented manner. Other studies indicate that RANTES has multiple aspects in immune responses. RANTES acts as a potent chemoattractant to localize and activate selectively the lymphoid cells such as monocytes, natural killer cells, dendritic cells, and memory T cells (26, 48, 58, 64) . Therefore, not only does RANTES play a role as a lymphocyte chemoattractant in acute immune cell functions of inflammation, it also, as our present findings imply, plays a role in adaptive immunity by, among other things, enhancing cytokine secretion and antibody production.
Intranasal immunization with CpG ODN plus SIV VLPs induced strong humoral and cellular immune responses. These responses were characterized by high levels of specific serum IgG, neutralizing antibodies, and IFN-␥-producing lymphocytes both in spleen and LN, by CTL responses, and by modest increases of the secretory IgA antibody. In particular, CpG ODN induced predominantly IgG2a anti-SIV Env antibodies and IFN-␥-producing lymphocytes; induction of these is indicative of Th1-type responses. Thus, CpG ODN can act as a potent mucosal adjuvant in combination with the VLP antigen for both humoral and systemic responses as well as both local and distant mucosal immunity. The effectiveness of CpG ODN as an adjuvant may be due to its ability to directly activate B cells (30, 43) and macrophages (63) to induce secretion of Th1 cytokines such as IFN-␥ and IL-12. In addition, through interactions with the Toll-like receptor 9 of dendritic cells (17) , CpG ODN has been shown to upregulate the expression of costimulatory molecules including class II MHC and B7 to produce Th1 polarizing cytokines and thus increase antigenpresenting dendritic cells (1, 7, 25, 61) . Therefore, this study and others provide evidence that CpG ODN is a potent adjuvant which works with a wide range of protein and particulate antigens and generally induces a Th1-biased immune response with CTL activity (9, 13, 39, 55) .
CT is a well-known mucosal adjuvant. Most studies on CT have demonstrated its adjuvanticity, focusing on induction of humoral immune responses. Here, we studied the effects of CT in inducing both humoral and cellular immune responses against the VLP antigen. Interestingly, addition of CT to VLP immunization increased both IgG2a and IgG1 antibodies, and the ratio of IgG2a to IgG1 was less than those obtained after the coadministration of RANTES or CpG. CT increased the numbers of both spleen and LN cells producing IFN-␥, whereas VLPs alone or VLPs coadministered with RANTES or CpG seem to induce more LN cells than splenocytes producing IFN-␥. In addition, CT induced the highest levels of IL-4-producing cells in both spleen and LN. However, RANTES and CpG did not increase IL-4-producing splenocytes and slightly decreased IL-4-producing LN cells compared with induction by immunization with VLPs alone. CT enhanced the levels of both CTL and proliferation responses in systemic (spleen and LN) and mucosal tissue (PP). Although numerous studies have described CT as a potent inducer of Th2-type immune responses, involving, for example, the IgG1 isotype antibody and IL-4 cytokine (32, 47, 71, 72) , we observed that CT is an effective mucosal adjuvant, inducing antibody responses as well as cellular responses including IFN-␥ and IL-4 secretions, CTL activities, and proliferation. This result is supported by other studies that demonstrate the capacity of CT to augment CTL responses to a soluble antigen after intranasal immunization (4, 54, 60) . Therefore, it is likely that CT can enhance the immune responses in both Th1-and Th2-like manners.
Most soluble protein antigens, when administrated intrana- FIG. 6 . Assessment of T-cell proliferation. Total lymphocytes isolated from naive and immune mice were incubated for 3 days in media containing T-helper-cell epitope peptides (see Materials and Methods). Proliferation of cells was determined by a nonradioactive proliferation assay. The proliferation index is presented as the factor of increase in absorbance (570 nm) on the basis of lymphocytes from nonimmunized-mouse controls. The OD 570 values for lymphocytes from nonimmunized mice used as negative controls were in the range of 0.1 to 0.2. Error bars, SEs for six mice in a group. The statistical significance of the difference between groups was calculated by Student's t test. ‫,ء‬ P Ͻ 0.02; ‫,ءء‬ P Ͻ 0.05. Naive, lymphocytes from nonimmunized mice used as baseline negative controls; VLP, SIV VLPs only; VϩRantes, SIV VLPs plus RANTES; VϩCpG, SIV VLPs plus CpG ODN; VϩCT, SIV VLPs ϩ CT.
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on September 7, 2017 by guest http://jvi.asm.org/ sally in the absence of an adjuvant, induce low or undetectable levels of immune responses (19, 41, 46, 66) . In contrast, VLPs are likely to induce both systemic and mucosal immune responses at relatively high levels compared to a soluble protein antigen. In addition, VLPs elicited higher levels of the serum IgG2a antibody specific to SIV Env than of the IgG1 antibody. This is quite interesting since soluble protein antigens even with CT or CT subunit B as the adjuvant preferentially induce IgG1 rather than IgG2a (34, 66) . This may reflect differences in the mechanism of antigen uptake compared with that for a soluble protein antigen which induces mostly IgG1 isotype serum antibodies. Supporting this idea, other studies indicate that uptake of particulate antigens may occur through M-like cells that overlie nasal lymphoid tissue (NALT) (62, 67) , which is probably the site of stimulation after intranasal immunization, whereas uptake of a soluble antigen may usually occur through the general nasal epithelium (31) . Several studies report that the NALT, like the gut-associated tissue, can stimulate the common mucosal immune system, in which immune cells stimulated at one site migrate to other sites through the systemic (blood and lymph) circulation (13, 41, 56, 65) . Also, it has been shown that intranasal immunization with an antigen resulted in disseminating antigen-sensitized lymphocytes (IgG and IgA antibody-secreting and cytokine-producing cells) from NALT to mucosal tissue as well as other lymphoid tissues through the cervical LN (16, 70) . In summary, both RANTES and CpG ODN are effective adjuvants in the context of VLP immunization at multiple mucosal surfaces and enhance systemic immune responses, which are characterized by Th1-type-oriented immune responses. Th1-type responses are desirable for immunization against numerous intracellular viral, bacterial, and parasitic pathogens. Most importantly, the levels of neutralization activities in both serum and vaginal secretions from mice immunized with VLPs coadministered with RANTES or CpG adjuvant were highly increased, to levels higher than those from mice coimmunized with CT. A safe and effective mucosal adjuvant such as RANTES and CpG ODN would therefore be of great value for developing more-effective mucosal AIDS vaccines.
